Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables

Journal of Clinical Pathology

Volumn 59, Issue 7, 2006, Pages 716-720

  Cross, Simon S ^a   Harrison, R F ^b   Balasubramanian, S P ^a   Lippitt, J M ^a   Evans, C A ^a   Reed, M W R ^a   Holen, I ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; BREAST CANCER; CLUSTER ANALYSIS; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RATING SCALE; TISSUE MICROARRAY;

APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CARRIER PROTEINS; CLUSTER ANALYSIS; FEMALE; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OSTEOPROTEGERIN; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL ANALYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745874700     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.030031     Document Type: Article

References (24)

1. Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal interact 2004;4:268-75.
2. Park HR, Min SK, Cho HD, et al. Expression of Osteoprotegerin and RANK ligand in breast cancer bone metastasis. J Korean Med Sci 2003;18:541-6.
3. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001;57:611-16.
4. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 2003;139:89-97.
5. Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 2003;18:1-6.
6. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy, Cytokine Growth Factor Rev 2003;14:337-48.
7. Holen I, Croucher PI, Hamdy FC, et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62:1619-23.
8. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004;86:269-79.
9. Bron LP, Scolyer RA, Thompson JF, et al. Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology 2004;36:561-5.
10. Shiraki K, Yamanaka T, Inoue H, et al. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int J Oncol 2005;26:1273-81.
11. Spierings DC, de Vries EG, Timens W, et al. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003;9:3397-405.
12. Reinholz MM, Iturria SJ, Ingle JN, et al. Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by realtime quantitative PCR. Breast Cancer Res Treat 2002;74:255-69.
13. Van Poznak C, Cross SS, Saggese M, et al. Expression of oesteoprotegerin (OPG), TNF-related apoptosis inducing ligand (TRAIL) and receptor activator of nuclear factor kappa beta ligand (RANKL) in human breast tumours. J Clin Pathol 2006;59:56-63.
14. Holen I, Cross SS, Neville-Webbe HL, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival? Breast Cancer Res Treat 2005;92:207-15.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology 1991;19:403-10.
16. Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005;103:164-73.
17. Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-92.
18. de Hoon MJ, Imoto S, Nolan J, et al. Open source clustering software. Bioinformatics 2004;20:1453-4.
19. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
20. Saldanha AJ. Java Treeview - extensible visualization of microarray data. Bioinformatics 2004;20:3246-8.
21. Nyambo R, Cross N, Lippitt J, et al. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 2004;19:1712-21.
22. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003;532:39-49.
23. Yagita H, Takeda K, Hayakawa Y, et al. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004;95:777-83.
24. Gulmann C, O'Grady A. Tissue microarrays: an overview. Curr Diagn Pathol 2003;9:149-54.